neorx
corp
said
granted
schwarz
pharma
ag
north
american
marketing
rights
biostent
device
restenosis
reclosing
arteries
following
balloon
angioplasty.in
exchange
schwarz
pharma
fund
future
development
product.neorx
said
retain
manufacturing
rights
worldwide
basis
marketing
rights
territories
outside
north
america
europe.depending
progress
product
development
neorx
receive
30
million
license
fees
milestone
payments
schwarz
pharma
direct
funding
future
development
estimated
additional
30
million
companies
said.neorx
receive
fees
based
future
sales
profits
manufacturing
product
